Climb Bio, Inc.
About Climb Bio, Inc.
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$59.9M
- Total assets
- $167.7M
- Market cap
- $604.1M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $67.9M
- Operating income
- -$67.9M
- Income tax
- $0
- Net income
- -$59.9M
- EPS (basic)
- $-0.88
- EPS (diluted)
- $-0.88
Balance sheet
- Total assets
- $167.7M
- Current assets
- $105.8M
- Total liabilities
- $7.3M
- Current liabilities
- $7.0M
- Shareholders’ equity
- $160.5M
Cash flow
- Operating cash flow
- -$54.4M
- Investing cash flow
- $2.8M
- Financing cash flow
- -$21.0K
- Net cash flow
- -$51.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $604.1M
- EPS (diluted)
- $-0.88
- Shares outstanding
- 55.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 10, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $59.9M.
- Trading 12% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Climb Bio, Inc..
Write a review
News about Climb Bio, Inc.
News & sentiment via Polygon.io
